Abstract

Published in 2008, by experts of the World Health Organization, the new classification of hematological malignancies forced a change of look at chromosomal aberrations and gene mutations, which are important in establishing the diagnosis and prognosis for patients with these malignancies. The new classification includes a new category of neoplasms – hematological malignancies with hypereosinophilia. Due to the high diversity of causes of hypereosinophilia and underlying genetic changes, their differential diagnosis is based on classical cytogenetics, fluorescence in situ hybridization (FISH) and genetic molecular techniques. Cytogenetic analysis of bone marrow cells showed that the majority of hypereosinophilia cases can be characterized by the presence of normal karyotype. Therefore, routine cytogenetic diagnostics should be complemented by FISH with break-apart probes for potentially rearranged genes (e.g. CBFB, ETV6) and unique probes for fusion genes (e.g. FIP1L1-PDGFRA), specific for hypereosinophilia-associated diseases. In differential diagnosis of hypereosinophilia, the analysis of characteristic gene mutations (e.g. cKIT) and gene fusions (e.g. ETV6-PDGFRB) is also applied, using molecular genetic methods.

References

• 1. Ackerman S.J., Bochner B.S.: Mechanisms of eosinophilia in thepathogenesis of hypereosinophilic disorders. Immunol. Allergy Clin.North. Am., 2007; 27: 357-375
  Google Scholar
• 2. Bain B.J., Gilliland D.G., Horny H.P., Vardiman J.W.: Myeloidand lymphoid neoplasms with eosinophilia and abnormalitiesof PDGFRA, PDGFRB or FGFR1. In: WHO classification of tumoursof haematopoietic and lymphoid tissues, eds.: S.H. Swerdlow, E.Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W.Vardiman. International Agency for Research on Cancer, Lyon2008, 68-73
  Google Scholar
• 3. Bain B.J., Gilliland D.G., Vardiman J.W., Horny H.P.: Chronic eosinophilicleukaemia, not otherwise specified. In: WHO classificationof tumours of haematopoietic and lymphoid tissues, eds.: S.H.Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J.Thiele, J.W. Vardiman. International Agency for Research on Cancer,Lyon 2008, 51-53
  Google Scholar
• 4. Baxter E.J., Hochhaus A., Bolufer P., Reiter A., Fernandez J.M.,Senent L., Cervera J., Moscardo F., Sanz M.A., Cross N.C.: The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.Hum. Mol. Genet., 2002; 11: 1391-1397
  Google Scholar
• 5. Chusid M.J., Dale D.C., West B.C., Wolff S.M.: The hypereosinophilicsyndrome: analysis of fourteen cases with review of the literature.Medicine, 1975; 54: 1-27
  Google Scholar
• 6. Cogan E., Schandené L., Crusiaux A., Cochaux P., Velu T., GoldmanM.: Clonal proliferation of type 2 helper T cells in a man withthe hypereosinophilic syndrome. N. Engl. J. Med., 1994; 330: 535-538
  Google Scholar
• 7. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., CortesJ., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A.,Malone J., Alam R., Schrier S.L. i wsp.: A tyrosine kinase created byfusion of the PDGFRA and FIP1L1 genes as a therapeutic target ofimatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med.,2003; 348: 1201-1214
  Google Scholar
• 8. Cools J., Quentmeier H., Huntly B.J., Marynen P., Griffin J.D., DrexlerH.G., Gilliland D.G.: The EOL-1 cell line as an in vitro model forthe study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.Blood, 2004; 103: 2802-2805
  Google Scholar
• 9. Crane M.M., Chang C.M., Kobayashi M.G., Weller P.F.: Incidenceof myeloproliferative hypereosinophilic syndrome in the UnitedStates and an estimate of all hypereosinophilic syndrome incidence.J. Allergy Clin. Immunol., 2010; 126: 179-181
  Google Scholar
• 10. Dmeńska H.: Zespół Hiper-IgE. Część I. Postać dziedziczona autosomalnierecesywnie (AR-HIES). Współcz. Alergol. Info., 2008; 3:152-156
  Google Scholar
• 11. Erben P., Gosenca D., Müller M. C., Reinhard J., Score J., Del ValleF., Walz C., Mix J., Metzgeroth G., Ernst T., Haferlach C., Cross N.C.,Hochhaus A., Reiter A.: Screening for diverse PDGFRA or PDGFRB fusiongenes is facilitated by generic quantitative reverse transcriptasepolymerase chain reaction analysis. Haematologica, 2010; 95: 738-744
  Google Scholar
• 12. Golub T.R., Barker G.F., Lovett M., Gilliland D.G.: Fusion of PDGFreceptor β to a novel ets-like gene, tel, in chronic myelomonocyticleukemia with t(5;12) chromosomal translocation. Cell, 1994; 77:307-316
  Google Scholar
• 13. Gotlib J.: Eosinophilic myeloid disorders: new classification andnovel therapeutic strategies. Curr. Opin. Hematol., 2010; 17: 117-124
  Google Scholar
• 14. Gotlib J., Cools J.: Five years since the discovery of FIP1L1-PDGFRA:what we have learned about the fusion and other molecularlydefined eosinophilias. Leukemia, 2008; 22: 1999-2010
  Google Scholar
• 15. Gotlib J., Cools J., Malone J.M.3rd, Schrier S.L., Gilliland D.G.,Coutré S.E.: The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilicsyndrome and chronic eosinophilic leukemia: implicationsfor diagnosis, classification, and management. Blood, 2004;103: 2879-2891
  Google Scholar
• 16. Hardy W.R., Anderson R.E.: The hypereosinophilic syndromes.Ann. Intern. Med., 1968; 68: 1220-1229
  Google Scholar
• 17. Haus O., Poluha A., Skonieczka K.: Cytogenetics in hematology.W: Molecular aspects of hematologic malignancies, red.: M. Witt, M.Dawidowska, T. Szczepański. Springer-Verlag, Berlin 2012, 161-181
  Google Scholar
• 18. Helbig G., Moskwa A., Hus M., Piszcz J., Swiderska A., UrbanowiczA., Całbecka M., Gajkowska J., Seferynska I., Hałasz M., Woszczyk D.,Markiewicz M., Krzemień S.: Clinical characteristics of patients withchronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRAfusion transcript – results of Polish multicentre study. Hematol.Oncol., 2010; 28: 93-97
  Google Scholar
• 19. Keene P., Mendelow B., Pinto M.R., Bezwoda W., MacDougall L.,Falkson G., Ruff P., Bernstein R.: Abnormalities of chromosome 12p13and malignant proliferation of eosinophils: a nonrandom association.Br. J. Haematol., 1987; 67: 25-31
  Google Scholar
• 20. Kuziemski K.: Eozynofilie płucne. Alergia, 2008; 2: 24-27
  Google Scholar
• 21. La Starza R., Specchia G., Cuneo A., Beacci D., Nozzoli C., LucianoL., Aventin A., Sambani C., Testoni N., Foppoli M., Invernizzi R.,Marynen P., Martelli M.F., Mecucci C.: The hypereosinophilic syndrome:fluorescence in situ hybridization detects the del(4)(q12) –FIP1L1/PDGFRA but not genomic rearrangements of other tyrosinekinases. Haematologica, 2005; 90: 596-601
  Google Scholar
• 22. Lierman E., Cools J.: ETV6 and PDGFRB: a license to fuse. Haematologica,2007; 92: 145-147
  Google Scholar
• 23. Macdonald D., Reiter A., Cross N.C.: The 8p11 myeloproliferativesyndrome: a distinct clinical entity caused by constitutive activationof FGFR1. Acta Haematologica, 2002; 107: 101-107
  Google Scholar
• 24. Montano-Almendras C.P., Essaghir A., Schoemans H., Varis I.,Noël L.A., Velghe A.I., Latinne D., Knoops L., Demoulin J.B.: ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitorcell proliferation and differentiation into eosinophils: therole of nuclear factor-κB. Haematol., 2012; 97: 1064-1072
  Google Scholar
• 25. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., PaternosterS.F., Shearer B.M., Reeder T.L., Li C.Y., Cross N.C., Cools J.,Gilliland D.G., Dewald G.W., Tefferi A.: CHIC2 deletion, a surrogatefor FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associatedwith eosinophilia and predicts response to imatinib mesylatetherapy. Blood, 2003; 102: 3093-3096
  Google Scholar
• 26. Poręba M., Rostoff P., Konduracka E., Pikul P., Rucińska M., PasowiczM., Piwowarska W.: Choroba endomiokardialna jako pierwszamanifestacja zespołu hipereozynofilowego. Kardiol. Pol., 2010;68: 440-445
  Google Scholar
• 27. Score J., Walz C., Jovanovic J.V., Jones A.V., Waghorn K., HidalgoCurtisC., Lin F., Grimwade D., Grand F., Reiter A., Cross N.C.: Detectionand molecular monitoring of FIP1L1-PDGFRA-positive diseaseby analysis of patient-specific genomic DNA fusion junctions. Leukemia,2009; 23: 332-339
  Google Scholar
• 28. Simon H.U., Rothenberg M.E., Bochner B.S., Weller P.F., WardlawA.J., Wechsler M.E., Rosenwasser L.J., Roufosse F., Gleich G.J., KlionA.D.: Refining the definition of hypereosinophilic syndrome. J. AllergyClin. Immunol., 2010; 126: 45-49
  Google Scholar
• 29. Valent P., Klion A.D., Rosenwasser L.J., Arock M., Bochner B.S.,Butterfield J.H., Gotlib J., Haferlach T., Hellmann A., Horny H.P.,Leiferman K.M., Metzgeroth G., Matsumoto K., Reiter A., RoufosseF. i wsp.: ICON: eosinophil disorders. World Allergy Organ. J., 2012;5: 174-181
  Google Scholar
• 30. Walz C., Score J., Mix J., Cillioni D., Roche-Lestienne C., YehR.F., Wiemels J.L., Ottaviani E., Erben P., Hochhaus A., Baccarani M.,Grimwade D., Preudhomme C., Apperley J., Martinelli G. i wsp.: Themolecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia,2009; 23: 271-278
  Google Scholar
• 31. Wilkins H.J., Crane M.M., Copeland K., Williams W.V.: Hypereosinophilicsyndrome: an update. Am. J. Hematol., 2005; 80: 148-157
  Google Scholar
• 32. Workman P., Aboagye E.O., Balkwill F., Balmain A., Bruder G.,Chaplin D.J., Double J.A., Everitt J., Farningham D.A., Glennie M.J.,Kelland L.R., Robinson V., Stratford I.J., Tozer G.M., Watson S. i wsp.:Guidelines for the welfare and use of animals in cancer research. Br.J. Cancer, 2010; 102: 1555-1577
  Google Scholar
• 33. Zmorzyński S., Filip A.A., Koczkodaj D., Michalak M.: Molekularnei cytogenetyczne czynniki prognostyczne w ostrej białaczceszpikowej (OBS). Postępy Hig. Med. Dośw., 2011; 65: 158-166
  Google Scholar

Full text